Thus, while Epag inhibits TET2 in TET dioxygenase–proficient bone marrow cells from patients with aplastic anemia, leading to HSPC expansion, in TET2-deficient leukemia cells it may restrict their growth because of their dependence on TET3 for demethylation of promoters and enhancers of survival and proliferative genes. Here, TET2 is linked to leukemia.